OakChart

Aardvark Therapeutics Inc

AARDHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 6:11 AM ET

1.370.00 (0.00%)
2026-11-11 14:13 CET
Market cap
29.98 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-69.89 USD m
Free cash flow, TTM
-69.41 USD m
EPS diluted, TTM
-3.21
P/E
-
Compare

Price

AARD against its 20, 50 and 200-day averages
2050200beat
2.505.007.5010.008.2M16.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AARDclose 1.3720-day 2.0950-day 3.93200-day 5.761.37

91.7% under 16.60 on 22 Jan 2026. Last 15 sessions, 363.4% high to low

Profile

AARD
52-week range, 3% of the way up
0.9316.60

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Employees40
IPOFeb 13, 2025
Beta4.29
ATR, 14d0.35
Rel volume0.02
Short float8.10%
Insider own41.42%
Inst own25.33%

Snapshot

6 groups

Valuation

Index-
Market Cap29.98M
Enterprise Value-43.21M
Income-69.89M
Sales0.00M
Book/sh3.42
Cash/sh3.38
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees40
IPOFeb 13, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.40
P/C0.41
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio12.63
Current Ratio12.63
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.21
EPS next Y-2.36
EPS next Q-0.72
EPS this Y-5.15%
EPS next Y23.46%
EPS next 5Y8.96%
EPS past 3/5Y-60.85% -
Sales past 3/5Y- -
EPS Y/Y TTM-89.45%
Sales Y/Y TTM-
EPS Q/Q0.56%
Sales Q/Q-
EarningsAug 11 AMC
EPS/Sales Surpr.24.52% -

Ownership

Insider Own41.42%
Insider Trans-0.84%
Inst Own25.33%
Inst Trans-6.84%
ROA-61.06%
ROE-66.02%
ROIC-93.09%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-34.42%
SMA50-65.15%
SMA200-76.23%
Trades-

Technical

Shs Outstand21.88M
Shs Float12.82M
Short Float8.10%
Short Ratio1.70
Short Interest1.04M
52W High16.60 -91.75%
52W Low0.93 47.31%
Volatility12.63% 20.32%
ATR (14)0.35
RSI (14)29.72
Beta4.29
Rel Volume0.02
Avg Volume609.37K
Volume507

Performance

Perf Week8.73%
Perf Month-66.09%
Perf Quarter-78.63%
Perf Half Y-79.21%
Perf YTD-89.56%
Perf Year-87.61%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom2.55
Target Price4.57
Prev Close1.37
Price1.37
Change %0.00%

Analyst ratings

latest 10 of 17
DateActionAnalystRating changeTargetImplied
Nov 05, 2026DowngradeRRaymond JamesStrong Buy → Mkt Perform
May 15, 2026DowngradeMMorgan StanleyEqual-Weight → Underweight$3+119.0%
Mar 02, 2026DowngradeSStifelBuy → Hold$6+338.0%
Mar 02, 2026DowngradeRRBC Capital MktsOutperform → Sector Perform$6+338.0%
Mar 02, 2026DowngradeMMorgan StanleyOverweight → Equal-Weight$7+410.9%
Mar 02, 2026DowngradeHH.C. WainwrightBuy → Neutral
Jan 28, 2026InitiatedRB. Riley SecuritiesBuy$32+2,235.8%
Dec 23, 2025InitiatedOOppenheimerOutperform$35+2,454.7%
Dec 12, 2025InitiatedWWilliam BlairOutperform
Dec 03, 2025InitiatedRRaymond JamesStrong Buy$47+3,330.7%

Peers

Mkt cap
TickerCompanyMkt cap
RYTMRhythm Pharmaceuticals Inc8.39B
HRMYHarmony Biosciences Holdings Inc1.98B
ACADAcadia Pharmaceuticals Inc3.15B
CRBPCorbus Pharmaceuticals Holdings Inc77.36M
PTNPalatin Technologies Inc12.23M
ALTAltimmune Inc383.20M
GPCRStructure Therapeutics Inc ADR1.57B
SKYESkye Bioscience Inc3.71M
VKTXViking Therapeutics Inc3.70B
AMLXAmylyx Pharmaceuticals Inc3.92B

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Sun NelsonSee RemarksSep 11 '26Sale5.1862,000321,17935,475Sep 11 08:14 PM
Sun NelsonSee RemarksSep 10 '26Sale5.0014,75473,77997,475Sep 11 08:14 PM
NELSON SUNOfficerSep 11 '26Proposed Sale5.0133,911169,894Sep 11 04:51 PM
NELSON SUNOfficerSep 10 '26Proposed Sale4.9242,843210,788Sep 10 05:18 PM
Sun NelsonChief Financial OfficerDec 11 '25Buy14.403,00043,200108,484Dec 12 08:30 PM
Lee Tien-LiChief Executive OfficerDec 11 '25Buy14.487,000101,3951,551,613Dec 12 08:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
VXFVanguard Extended Market Index ETFAUM: 30.61B
IBBiShares Biotechnology ETFAUM: 11.47B
IWCiShares Micro-Cap ETFAUM: 1.23B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 112.22M
DXUVUS Vector Equity Portfolio ETF Class SharesAUM: 666.18M
IBBQInvesco Nasdaq Biotechnology ETFAUM: 131.39M
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 213.08M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 109.26M

News

latest 14 of 138
  • Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials (GlobeNewswire) -64.81%
  • Aardvark Therapeutics stock surges as FDA lifts clinical hold (Investing.com) -10.43%
  • Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data (GlobeNewswire)
  • Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD (PR Newswire) -6.51%
  • Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors (GlobeNewswire) -5.04%
  • Loading…
  • If You Lost Money Investing in Aardvark Therapeutics, Inc. (AARD) Contact Robbins LLP for Information About Recovering Your Losses (Newsfile)
  • Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.31%
  • Robbins LLP is Investigating Allegations that Aardvark Therapeutics, Inc. Misled Investors Regarding the Viability and Efficacy of its Lead Drug Candidate ARD-101 (Newsfile) +7.38%
  • AARD Stockholders Have Rights - If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses (Business Wire) -6.11%
  • Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately (PR Newswire) +5.38%
  • Did You Lose Money Investing in Aardvark Therapeutics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AARD (Newsfile)
  • Aardvark Therapeutics Inc (AARD) (Q2 2026) Earnings Call Highlights: Board Re-Elected, Auditor ... (GuruFocus.com)
  • Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) -8.62%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-11-0.660-0.874-0.6600.000.0012
2026Q12026-05-07-0.990-0.877-0.9900.000.0012
2025Q42026-03-23-0.810-0.827-0.8070.000.0011
2025Q32025-11-13-0.750-0.799-0.7500.000.007
2025Q22025-08-13-0.660-0.600-0.6620.000.004
2025Q12025-05-14-0.710-0.673-0.4290.000.003
2024Q42025-03-31-0.250-0.410-0.4050.000.002
2026Q3---0.725--0.0011
2026Q4---0.688--0.0011
2027Q1---0.615--0.004
2027Q2---0.583--0.004
2027Q3---0.528--0.004
2027Q4---0.533--0.004
2028Q1---0.726---1
2028Q2---0.819---1
2028Q3---0.939---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-5.150-2.855-0.9490.000.00
2025FY-2.930-2.932-2.9300.000.00
2026FY--3.081--0.00
2027FY--2.358--0.00
2028FY--2.211--2.31
2029FY--1.160--104.38
2030FY-0.240--250.6

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-257000.000.000.00
2026Q3S2026-10-238000.000.000.00
2026Q3S2026-10-087000.000.000.00
2026Q3S2026-08-128000.000.000.00
2026Q3S2026-07-178000.000.000.00
2026Q3S2026-07-027000.000.000.00
2026Q3S2026-05-088000.000.000.00
2026Q3S2026-05-077000.000.000.00
2026Q3S2026-03-247000.000.000.00
2026Q3S2026-02-274000.000.000.00
2026Q3S2026-01-263000.000.000.00
2026Q3S2025-12-112000.000.000.00
2026Q3S2025-12-011000.000.000.00
2026Q3S2025-10-041000.000.000.00

Estimate history

EPS, annual-0.634-0.337-0.949-2.64-3.2051
Period2022202320242025TTM
EPS, quarterly-2.128-0.196-0.405-0.429-0.662-0.75-0.807-0.99-0.659
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00000
Period2022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual21.38421.38421.69621.81521.884
Period2022202320242025MRQ
Shares, quarterly2.5621.38421.69621.68821.69321.74521.81521.81621.884
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue0.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.040.040.020.100.11
Gross Profit-0.04-0.04-0.02-0.10-0.11
Selling, General and Administrative Excl. Other73.9162.6922.777.3211.25
Research and Development55.0248.9017.364.487.17
Other Operating Expense0.000.000.000.000.00
Operating Income-73.95-62.73-22.79-7.42-11.36
Interest Expense0.000.000.00--
Unusual Expense-0.010.010.221.222.32
Net Income Before Taxes-69.89-57.59-20.59-7.21-13.56
Income Taxes0.000.000.000.000.00
Consolidated Net Income-69.89-57.59-20.59-7.21-13.56
Net Income From Continuing Operations-69.89-57.59-20.59-7.21-13.56
Net Income-69.89-57.59-20.59-7.21-13.56
EPS (Recurring)-3.20-2.64-0.94-0.30-0.56
EPS (Basic, Before Extraordinaries)-3.21-2.64-0.95-0.34-0.63
EPS (Diluted)-3.21-2.64-0.95-0.34-0.63
EBITDA-73.91-62.69-22.77-7.32-11.25
Non-Operating Income (Expense)4.065.142.411.420.12
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense7.043.950.440.410.31
Shares Outstanding21.8821.8221.7021.3821.38
Market Capitalization29.9829.98287.95--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.010.010.010.000.09
Gross Profit-0.01-0.01-0.01-0.01-0.01-0.010.00-0.09
Selling, General and Administrative Excl. Other15.0722.4518.6917.6915.8410.469.455.00
Research and Development10.4416.5614.2913.7313.137.758.064.06
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-15.08-22.46-18.70-17.70-15.85-10.47-9.45-5.09
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-0.000.010.02-0.040.010.010.050.09
Net Income Before Taxes-14.39-21.59-17.60-16.32-14.37-9.31-8.78-4.18
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-14.39-21.59-17.60-16.32-14.37-9.31-8.78-4.18
Net Income From Continuing Operations-14.39-21.59-17.60-16.32-14.37-9.31-8.78-4.18
Net Income-14.39-21.59-17.60-16.32-14.37-9.31-8.78-4.18
EPS (Recurring)-0.66-0.99-0.81-0.75-0.66-0.43-0.40-0.19
EPS (Basic, Before Extraordinaries)-0.66-0.99-0.81-0.75-0.66-0.43-0.40-0.20
EPS (Diluted)-0.66-0.99-0.81-0.75-0.66-0.43-0.40-0.20
EBITDA-15.07-22.45-18.69-17.69-15.84-10.46-9.57-5.00
Non-Operating Income (Expense)0.690.891.121.351.491.180.721.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.952.001.581.500.630.230.170.14
Shares Outstanding21.8821.8221.8221.7521.6921.6921.7021.38
Market Capitalization29.9882.25285.77288.35293.33160.60165.52-

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments110.0373.669.9916.11
Short Term Receivables0.000.000.000.00
Inventories0.000.000.000.00
Other Current Assets1.860.470.380.39
Total Current Assets111.8974.1410.3716.49
Net Property, Plant & Equipment0.350.730.150.25
Total Investments and Advances0.000.000.000.00
Other Assets4.942.630.010.01
Total Assets117.1877.5110.5416.76
Short Term Debt Incl. Current Port. of LT Debt0.440.340.110.10
Accounts Payable2.072.300.000.00
Other Current Liabilities8.042.291.270.49
Total Current Liabilities10.554.931.380.59
Long Term Debt0.000.4443.9544.07
Provision for Risks Charges0.000.000.000.00
Other Liabilities0.000.030.000.02
Total Liabilities10.555.3945.3444.68
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.00126.760.000.00
Common Equity106.63-54.64-34.80-27.92
Total Shareholders Equity106.6372.11-34.80-27.92
Accumulated Minority Interest0.000.000.000.00
Total Equity106.6372.11-34.80-27.92
Total Liabilities & Stockholders Equity117.1877.5110.5416.76
Book Value Per Share4.89-2.52-1.63-1.31
Tangible Book Value Per Share4.89-2.52-1.63-1.31
Full-Time Employees4022--
Price to Book Ratio0.402.35--
Return on Assets-59.16-46.77-52.82-
Return on Equity-64.44-110.36--
Return on Invested Capital-54.01-28.38-78.76-84.02
Quick Ratio10.6115.057.5027.72
Current Ratio10.6115.057.5027.72

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-69.89-57.59-20.59-7.21-13.56
Depreciation0.040.040.02--
Other Funds (Non Cash)6.633.03-0.281.474.33
Funds from Operations-63.22-54.53-20.85-5.74-9.23
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-6.190.361.57-0.08-1.31
Cash from Operating Activities-69.41-54.17-19.28-5.82-10.54
Capital Expenditures-0.00-0.10-0.110.000.00
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments116.55-49.57-11.890.000.00
Purchase of Investments-4.95-129.60-11.890.000.00
Sale Or Maturity of Investments121.5080.030.000.000.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities116.55-49.67-12.000.000.00
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock0.7189.2583.180.000.23
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock0.7189.2583.180.000.23
Proceedsfrom Stock Options0.4588.8882.850.000.00
Issuance or Reduction of Debt, Net0.000.000.000.00-1.00
Change in Long Term Debt0.000.000.000.00-1.00
Issuance of Long Term Debt0.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00-1.00
Net Financing Active Other Cash Flow0.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities0.7189.2583.180.00-0.78
Net Change in Cash47.85-14.5951.91-5.82-11.32
Free Cash Flow-69.41-54.27-19.39-5.82-10.54
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments73.8791.20110.03126.35141.82151.26
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets6.792.381.862.862.953.29
Total Current Assets80.6693.58111.89129.21144.77154.55
Net Property, Plant & Equipment0.630.270.350.440.520.63
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.174.744.943.582.191.84
Total Assets81.4698.59117.18133.23147.47157.03
Short Term Debt Incl. Current Port. of LT Debt0.400.340.440.430.420.39
Accounts Payable2.094.492.074.445.062.56
Other Current Liabilities3.906.788.045.864.843.03
Total Current Liabilities6.3911.6010.5510.7410.315.98
Long Term Debt0.280.000.000.120.230.34
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.010.02
Total Liabilities6.6611.6010.5510.8510.556.34
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity74.8086.99106.63122.38136.93150.69
Total Shareholders Equity74.8086.99106.63122.38136.93150.69
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity74.8086.99106.63122.38136.93150.69
Total Liabilities & Stockholders Equity81.4698.59117.18133.23147.47157.03
Book Value Per Share3.423.994.895.636.316.95
Tangible Book Value Per Share3.423.994.895.636.316.95
Full-Time Employees55-4072-54
Price to Book Ratio0.400.772.332.111.95-2.98
Return on Assets-61.06-54.67-59.16-44.96--
Return on Equity-66.02-58.79-64.44-48.06--
Return on Invested Capital-19.16-24.82-16.50-13.32-10.48-6.16
Quick Ratio12.638.0610.6112.0314.0425.86
Current Ratio12.638.0610.6112.0314.0425.86

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-14.39-21.59-17.60-16.32-14.37-9.31
Depreciation0.010.010.010.010.010.01
Other Funds (Non Cash)2.021.993.84-1.210.130.27
Funds from Operations-12.36-19.59-13.75-17.52-14.23-9.03
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-5.240.72-0.67-1.004.38-2.36
Cash from Operating Activities-17.60-18.87-14.42-18.52-9.84-11.39
Capital Expenditures0.000.000.00-0.00-0.090.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments28.7534.2524.3029.259.50-112.62
Purchase of Investments0.000.00-4.950.000.00-124.65
Sale Or Maturity of Investments28.7534.2529.2529.259.5012.03
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities28.7534.2524.3029.259.41-112.62
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.260.00-2.112.56-0.0788.88
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.260.00-2.112.56-0.0788.88
Proceedsfrom Stock Options0.260.00-2.192.39-0.0888.77
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.260.00-2.112.56-0.0788.88
Net Change in Cash11.4115.387.7713.29-0.51-35.14
Free Cash Flow-17.60-18.87-14.42-18.52-9.94-11.39

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.10%1.0M12.8M584.55K
2026-10-154.32%0.6M12.8M133.93K
2026-09-303.70%0.5M12.8M216.28K
2026-09-153.31%0.4M12.8M254.14K
2026-08-314.00%0.5M12.7M249.06K
2026-08-144.80%0.6M12.7M266.33K
2026-07-315.13%0.7M12.7M268.15K
2026-07-155.13%0.7M12.7M269.50K
2026-06-304.20%0.5M12.6M195.08K
2026-06-157.27%0.9M12.6M192.88K
2026-05-297.87%1.0M12.6M300.00K
2026-05-158.08%1.0M12.6M289.97K
2026-04-3010.46%1.3M12.1M282.50K
2026-04-159.55%1.2M12.1M291.00K
2026-03-319.40%1.1M12.1M288.39K
2026-03-1311.50%1.4M12.0M278.00K
2026-02-2715.02%1.8M12.0M191.93K
2026-02-1315.62%1.9M12.0M199.42K
2026-01-3014.20%1.8M12.5M201.38K
2026-01-1512.99%1.6M12.5M202.40K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.100.030.0003030.000.921-0.0300.000
call5.000.004.100.015.9252350.000.199-0.0190.001
call7.500.002.500.656.0122590.000.110-0.0130.000
call10.000.001.550.9027.4832.000.000.974-0.0180.000
call12.500.004.900.507.12777.000.000.100-0.0140.000
call15.000.004.900.007.5140.000.000.097-0.0140.000
put2.500.004.901.200.00043.000.00-0.742-0.0130.001
put5.001.206.003.750.00096.000.00-0.801-0.0180.001
put7.503.708.502.600.0002400.00-0.890-0.0120.000
put10.006.1011.004.800.0000.000.00-0.897-0.0130.000
put12.5010.2013.506.660.0000.000.00-0.901-0.0130.000
put15.0011.1016.000.000.0000.000.00-0.904-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-10-238-KCurrent report2026-10-23SEC
2026-10-228-KCurrent report2026-10-22SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-10-083Initial statement of beneficial ownership of securities2026-10-07SEC
2026-10-088-KCurrent report2026-10-06SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-10144Filing for proposed sale of securities under Rule 144.SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-178-KCurrent report2026-08-14SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-10ARSAnnual report to security holders. 2025-12-31SEC
2026-07-10DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-14SEC
2026-06-29PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-14SEC
2026-06-128-KCurrent report2026-06-10SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-03EFFECTEffectiveness filing by commission orderSEC
2026-04-03424B5SEC
2026-03-30CORRESPSEC
2026-03-25UPLOADUpload SubmissionSEC
2026-03-248-KCurrent report2026-03-23SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900394.96K2
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-12144.60K200
2025-110000

Institutional holders

Manager% owned
Decheng Capital LLC17.96%
CITADEL ADVISORS LLC5.88%
Laurion Capital Management LP4.73%
VANGUARD CAPITAL MANAGEMENT LLC2.58%
AQR CAPITAL MANAGEMENT LLC2.20%
EcoR1 Capital, LLC1.82%
ADAGE CAPITAL PARTNERS GP, L.L.C.1.38%
CANTOR FITZGERALD, L. P.1.07%
BlackRock, Inc.0.86%
GEODE CAPITAL MANAGEMENT, LLC0.64%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.87%
VANGUARD EXTENDED MARKET INDEX FUND0.64%
Fidelity Small Cap Index Fund0.58%
iShares Biotechnology ETF0.41%
Fidelity Extended Market Index Fund0.31%
VANGUARD RUSSELL 2000 INDEX FUND0.30%
iShares Micro-Cap ETF0.20%
Schwab Small-Cap Index Fund0.13%
Ultra-Small Company Market Fund0.11%
Fidelity Total Market Index Fund0.10%

OakChart. AARD. Cached 15 minutes.